You are here: REPAIR trial homepage


London School of Hygiene & Tropical Medicine
Worldwide research and postgraduate education in global health

UKCRC registered Clinical Trials Unit

Sponsored by UCL

This research is funded by the Efficacy and Mechanism Evaluation (EME) programme. The EME programme is funded by the MRC and managed by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC), based at the University of Southampton

Renal protection against ischaemia-reperfusion in transplantation: a randomised double blind placebo-controlled trial of 400 living-donor renal transplant patients


406 patients randomised

Recruitment has now closed

Many thanks to everyone involved for helping to exceed our target

The purpose of the trial is to determine if remote ischaemic preconditioning (RIPC) improves renal function after transplantation.

Primary objective
To determine the effect of RIPC on glomerular filtration rate (GFR) 12 months after transplantation.

Secondary objectives
To determine the effects of RIPC on
1. Rate of fall in creatinine in the first 72 hours after transplantation
2. Inflammatory response to surgery in the first 5 days after transplantation
3. Protein expression in kidney parenchyma samples using histochemistry
4. Protein activation and expression in renal vasculature using immunoblotting
5. Kidney fibrosis 6 months after transplantation
6. Alloreactivity of T cells in the first 18 months after transplantation
7. Patient outcomes 2-5 years after transplantation using renal registry data
Inclusion criteria
1. Patients undergoing living donor transplantation
2. Patients aged 18 years and above
Exclusion criteria
1. Patients on ATP-sensitive potassium channel opening or blocking drugs
2. Patients on ciclosporin
3. Patients with a known iodine sensitivity (who cannot undergo iohexol clearance studies)
4. Patients with ABO incompatability
5. Any patient requiring HLA antibody removal therapy

Last updated 19 July 2013 Repair trial